• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Criteria for diagnosis of arrhythmogenic cardiomyopathy (ACM) were first proposed in 1994
and revised in 2010 by a Task Force. Although the Task Force criteria demonstrated a good …

Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disease characterised by
substitution of the ventricular myocardium by fibrofatty tissue. 1 The disease was originally …

The original designation of “Arrhythmogenic right ventricular (dysplasia/) cardiomyopathy”(
ARVC) was used by the scientists who first discovered the disease, in the pre-genetic and …

Arrhythmogenic cardiomyopathy (ACM) is a heart muscle disease characterized by
prominent “non-ischemic” myocardial scarring predisposing to ventricular electrical …

There is increasing evidence regarding the prevalence of genetic cardiomyopathies, for
which arrhythmias may be the first presentation. Ventricular and atrial arrhythmias …

Cardiac magnetic resonance (CMR) has become an essential tool for the evaluation of
patients affected or at risk of developing cardiomyopathies (CMPs). In fact, CMR not only …

Background: Left ventricular (LV) scar on late gadolinium enhancement (LGE) cardiac
magnetic resonance has been correlated with life-threatening arrhythmic events in patients …

Background Mutations in filamin-C (FLNC) are involved in the pathogenesis of
arrhythmogenic cardiomyopathy (ACM) and dilated cardiomyopathy (DCM), and have been …